US20040167098A1 - Cross-linked polysaccharides - Google Patents

Cross-linked polysaccharides Download PDF

Info

Publication number
US20040167098A1
US20040167098A1 US10/787,736 US78773604A US2004167098A1 US 20040167098 A1 US20040167098 A1 US 20040167098A1 US 78773604 A US78773604 A US 78773604A US 2004167098 A1 US2004167098 A1 US 2004167098A1
Authority
US
United States
Prior art keywords
cross
polysaccharide
linked
product
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/787,736
Inventor
Rolando Barbucci
Giancarlo Sportoletti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigmar Italia SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11381036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040167098(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/787,736 priority Critical patent/US20040167098A1/en
Publication of US20040167098A1 publication Critical patent/US20040167098A1/en
Assigned to SIGMA ITALIA SPA reassignment SIGMA ITALIA SPA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FARMILA-THEA FARMACEUTICI S.P.A.
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/005Crosslinking of cellulose derivatives
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00Preparation of derivatives of starch
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00Preparation of derivatives of starch
    • C08B31/003Crosslinking of starch
    • C08B31/006Crosslinking of derivatives of starch
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Definitions

  • the present invention refers to a cross-linking process of carboxylated polysaccharides.
  • the process of the invention provides a high degree of reproducibility of the obtained products, in terms of cross-linking degree, homogeneity of the distribution of the cross-linking chains, and chemico-physical characteristics of the products and the technological characteristics of the articles obtained therefrom.
  • the invention further refers to the products obtainable by said process and their applications in the medical, pharmaceutical and dermo-cosmetic field.
  • Macromolecules are used in the preparation of pharmaceutical formulations as thickening agents, lubricants, gastro-resistant film coating agents, particularly in the preparation of capsules, gel, colloids and of different devices (e.g. contact lenses, gauzes, etc.). Macromolecules are also used in the preparation of controlled-release formulations of active ingredients.
  • Said macromolecules belong to different chemical families and may be either synthetic, or natural or semi-synthetic.
  • Examples of synthetic macromolecules include polyvinylpyrrolidone, polyoxyethylenealkyl ethers, polyvinyl alcohols, polymethacrylates.
  • Examples of natural macromolecules include native hyaluronic acid (HY) and cellulose.
  • Examples of semi-synthetic macromolecules include carboxyalkylcelluloses, widely used in the food and personal care industries. These macromolecules are characterized by a linear or poorly branched structure.
  • cross-linking A very important modification for increasing the chemical, enzymatic and mechanical strength is provided by cross-linking, which may be carried out both on synthetic and natural (more or less already modified) polymers.
  • cross-linked polymers include polymers used for the gastro-protection of tablets or capsules (polymethacrylates), as well as polymers used as emulsifiers, suspending agents, tablet hardeners (Carbopol), cross-linked hyaluronic acids, hereinafter discussed.
  • a gradual degradation for instance for the controlled release of a medicament, may be desirable.
  • This resistance is particularly important when the macromolecule is present in compositions/articles that must last for a long time, e.g. substitutes of the synovial liquid, films, sponges or gels as tissular antiadhesives in different kinds of surgery; in tissular engineering (artificial organs); artificial skins, in the treatment of burns and generally in aesthetic surgery;
  • composition of the different production batches must be kept constant within very narrow limits; this implies that the production methods are standardized and that the base components have a very low intrinsic variability.
  • a possible cause of dishomogeneity for macromolecules derives from the dispersion of molecular weights. Said dishomogeneity becomes even higher as a consequence of cross-linking. This may be a serious drawback depending on the field of use and the applicative purposes of the final product.
  • EP-A-566118 discloses cross-linked polysaccharides to be used as super-absorbents for diapers and similar articles.
  • the process described therein is based on the cross-linking of cellulose by formation of intermolecular amides, esters or ethers between polyamines, polyols or mixtures thereof and the carboxy group of polysaccharides.
  • the reaction is carried out by heating at about 80° C. the mixture of the polysaccharide with the polyol and/or polyamine. This process is certainly economic and suitable for large scale production where the reproducibility requirements are less stringent.
  • U.S. Pat. No. 5,465,055 discloses cross-linked polysaccharides (hyaluronic acid and alginic acid) obtained by esterification of COOH of the polysaccharide and OH groups of other molecules, without insertion of cross-linking arms.
  • WO 91/9119 discloses microcapsules for islets of Langerhans as biohybrid organs, consisting of alginic acid cross-linked with barium ions.
  • EP 190215 discloses the cross-linking of different polymers (carboxylated starches, dextran, celluloses) with di- or poly-functional epoxides.
  • polyalcohols are disclosed in U.S. Pat. No. 4,957,744;
  • divinylsulfone is disclosed in U.S. Pat. Nos. 4 , 605 , 691 , 4 , 636 , 524 ;
  • aldehydes are disclosed in U.S. Pat. Nos. 4,713,448 and 4,582,865;
  • carboxamides are disclosed in U.S. Pat. No. 5,356,833;
  • the invention refers to a process for the preparation of cross-linked polysaccharides containing carboxy groups, allowing complete control of cross-linking degree as well as high reproducibility in terms of constant characteristics of the final product.
  • the process of the invention comprises:
  • the obtained cross-linked polysaccharide may be subjected to sulphation or hemisuccinylation of the free hydroxy groups.
  • the products obtainable by the process of the invention may also be complexed with metal ions such as zinc, copper or iron ions.
  • the carboxy-containing polysaccharide which may be used according to the invention may be of natural, synthetic or semi-synthetic origin.
  • said polysaccharides include Hyaluronic acids (obtained from tissues or bacteria), carboxymethyldextran, carboxymethylcellulose, carboxymethyl-starch, alginic acids, cellulosic acid, N-carboxy-methyl or butyl glucans or chitosans; heparins with different molecular weights, optionally desulphated and succinylated, dermatan sulphates, Chondroitin sulphates, heparan sulphates, polyacrylic acids.
  • Hyaluronic acids carboxymethylcellulose, heparins, alginic acids and polyacrylic acids are particularly preferred.
  • the carboxy activating agents are usually those used in the peptide chemistry: examples of suitable agents include carbonyldiimidazole, carbonyltriazole, chloromethylpyridylium iodide (CMP-J), hydroxybenzotriazole, p-nitrophenol p-nitrophenyltrifluoroacetate, N-hydroxysuccinimide and the like.
  • CMP-J chloromethylpyridylium iodide
  • hydroxybenzotriazole p-nitrophenol p-nitrophenyltrifluoroacetate
  • N-hydroxysuccinimide and the like.
  • chloromethylpyridylium iodide is particularly preferred.
  • the polyamines have preferably the following general formula:
  • R 1 and R 2 which are the same or different, are hydrogen, C 1 -C 6 alkyl, phenyl or benzyl groups
  • A is a C 2 -C 10 alkylene chain, preferably a C 2 -C 6 alkylene chain, optionally substituted by hydroxy, carboxy, halogen, alkoxy, amino groups; a polyoxyalkylene chain of formula
  • n is 2 or 3 and m is an integer from 2 to 10; a C 5 -C 7 cycloalkyl group; an aryl or hetaryl group, preferably 1, 3 or 1,4-disubstituted benzene.
  • A is preferably C 2 -C 6 linear alkylene or a chain of formula
  • the cross-linking reaction is preferably carried out in a solvent selected from tetrahydrofuran, dimethylformamide or dimethyl sulfoxide, and the polysaccharide is preferably salified with a lipophilic cation, for example tetralkylammonium or other lipophilic organic bases.
  • inorganic salts such as sodium salts
  • suitable organic lipophilic salts may be carried out by known ion-exchange methods in homogeneous phase or by precipitation of the acidic component, followed by recovering of the latter and salification with the desired organic base.
  • the activation reaction of the carboxy groups is carried out in homogeneous phase and in anhydrous polar aprotic solvent.
  • the polyamine diluted in the same anhydrous solvent is added to the solution of the activated ester, keeping the temperature from 0° C. to 30° C.
  • the cross-linking reaction times range from 1 to 12 hours, also depending on the optional presence of suitable basic substances (e.g. triethylamine).
  • the final product is recovered by precipitation of the organic salt adding a different solvent to the reaction solvent or by evaporation of the latter, followed by centrifugation, washing with distilled water, repeated dispersions in the solutions of the desired alkali (for instance sodium, potassium), subsequent washing with water and final drying of the alkaline salt under vacuum or by lyophilization.
  • a different solvent for instance sodium, potassium
  • dispersions in the solutions of the desired alkali for instance sodium, potassium
  • the cross-linking degree may range within wide limits and may be adjusted by changing the amount of the carboxy activating agents, since the activation and the cross-linking reaction are substantially quantitative.
  • the cross-linked polysaccharides obtained according to the invention may be subjected to sulphation reaction of the hydroxy groups possibly present, usually by reaction with the pyridine-sulfur trioxide complex in dimethylformamide.
  • the reaction is carried out in heterogeneous phase at a temperature of 0-10° C. for times ranging from about 0.5 to about 6 hours.
  • the sulphation degree obtained is comprised within wide limits with respect to the total of the hydroxy groups and it may be adjusted by changing the temperature and reaction times.
  • the sulphation degree (defined as equivalents of sulphate groups/g) may range from 1 ⁇ 10 ⁇ 6 to 6 ⁇ 10 ⁇ 6 , preferably it is of 2 ⁇ 10 ⁇ 6 eq/g for a cross-linking degree of 0.5.
  • cross-linked polymers obtained according to the invention are able to complex metal ions such as zinc, copper or iron ions.
  • Said complexes may be obtained by dissolving or dispersing until complete swelling the product in water and adding under stirring, preferably at room temperature, a concentrated solution of an organic or inorganic metal salt, e.g. CuCl 2 , ZnCl 2 , Fe 2 (SO 4 ); after stirring for 12-24 hours, the complex is recovered by centrifugation or by precipitation following the addition of a different solvent (for example ethanol or acetone) or evaporation under vacuum; the recovered crude product is thoroughly washed with distilled water so as to remove the excess ions. The complexes are then lyophilized.
  • the content of metal ions varies depending on the used operative conditions, particularly the polymer to ion molar ratios; concentration and pH of the solutions; reaction times and particularly cross-linking degree.
  • the process of the invention by suitably adjusting the cross-linking and/or sulphation degree, allows the preparation of cross-linked carboxylated polysaccharides in a wide range of shapes, characterized by different properties such as viscoelasticity, hydration degree, complexing ability towards metal ions, ability to form hydrogels, moldability in films or sponges, mechanical strength of the final materials.
  • the molar ratio was 1 to 1 as carboxymethyl cellulose has one functional carboxylic group per disaccharide unit. After 20 minutes the solution was added with 2 ml of cross-linking 1,3-diaminopropane (0.006 moles), and immediately after also with 0.5 ml of triethylamine. A solid, jelly-like product formed which was washed with DMF, then placed in H 2 O to completely swell.
  • TBA salt of alginic has been prepared from the sodium salt by ionic exchange on strong cationic resin (Dovex) in H + form (i.e. acidic form), followed by neutralization with tetrabutylammonium hydroxide (TBA-OH) and final liophylisation.
  • Dovex strong cationic resin
  • TBA-OH tetrabutylammonium hydroxide
  • Hyaluronic acid sodium salt (1 ⁇ 10 ⁇ 3 mol., with reference to the disaccharidic unit) were transformed in TBA salt, according to one of the following methods:
  • a) 1% aqueous solution of sodium hyaluronate is transformed in H + form by H + cationic strong resin (Amberlite IR 120); the final solution is treated by a 0.5% solution of TBA-OH to about pH 9.
  • TBA salt is then dissolved in 15 ml of anhydrous DMF, under N 2 , and—at 0° C.-0.02 g of cloromethypyridylium Iodide (CMPJ) in 2 ml of anhydrous DFM, are added dropwise to the stored solution of TBA salt.
  • CMPJ cloromethypyridylium Iodide
  • d 1,3-diaminopropane
  • the reaction mixture was stirred for at least 30′ and the solvent was then removed under reduced pressure, the residue was then taken up with DMF, which was subsequently removed by distillation; the residue was then treated with ethanol, ethanol-water and finally with water.
  • SD Silicone (Swelling Degree, in water and r.t., after 15′; gravimetric determination; calculated according to: SD ⁇ W s - Wd Wd ⁇ 100 ,
  • Cross-linking degree 0.05 (5% of initially available carboxy groups).
  • Activator chloromethylpyridylium iodide.
  • the final product after lyophilisation, shows at the scanning microscope an irregular pattern with smooth zones alternating to spongy zones.
  • the cross-linking degree was 0.3 (30% of initially available carboxy groups)
  • hyaluronic acid tributylammonium salt (HY TBA) (1 ⁇ 10 ⁇ 3 mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of DMF under nitrogen.
  • CMPJ chloromethylpyridylium iodide
  • the obtained product had a cross-linking degree of 0.5 and showed at the scanning microscope a grainy aspect interspaced by large meshes. At higher magnitudes, the two morphologies appear identical and show round-shaped protrusions a few microns in diameter.
  • IR film; cm ⁇ 1 ): 1740 (— CO OH); 1630 (— CO —NH—); 1610 (— CO O ⁇ ); 1560 (—CO—NH—);
  • NMR (13 C; ppm): 29.3 and 39.8 (—CH 2 —CH 2 —CH 2 — propanediamine link); 172.5
  • the IR spectrum shows, in addition to the bands of the starting product, a peak at 1260 cm ⁇ 1 and a stronger band at 1025 cm ⁇ 1 .
  • the rheological properties are characterised by dynamic elastic modules G′ (2500 Pa with 20 mg and 1000 Pa with 10 mg at 10 Hz) which are always higher than the dynamic viscous modules G′′ (600 Pa with 20 mg and 150 Pa with 10 mg at 10 Hz) and much higher than the corresponding values obtained with non-sulphated HY (13 at 50%—example 5).
  • This compound has a thrombin time (TT) higher (61 ⁇ 5”) than the control (14.0′′) and the corresponding not cross-linked (14.6′′).

Abstract

A product having application in the medical, pharmaceutical and dermo-cosmetic fields comprising a cross-linked polysaccharide in which cross-linkage exists only through amide bonds between carboxy groups of the polysaccharide and amino groupss of a polyamine.

Description

  • The present invention refers to a cross-linking process of carboxylated polysaccharides. [0001]
  • The process of the invention provides a high degree of reproducibility of the obtained products, in terms of cross-linking degree, homogeneity of the distribution of the cross-linking chains, and chemico-physical characteristics of the products and the technological characteristics of the articles obtained therefrom. [0002]
  • The reproducibility is particularly important for the applications in the medical, pharmaceutical and dermo-cosmetic fields. [0003]
  • The invention further refers to the products obtainable by said process and their applications in the medical, pharmaceutical and dermo-cosmetic field. [0004]
  • BACKGROUND OF THE INVENTION
  • The use of macromolecules in the medical/pharmaceutical field and, more recently, in the dermatological-cosmetic field, is well established. Macromolecules are used in the preparation of pharmaceutical formulations as thickening agents, lubricants, gastro-resistant film coating agents, particularly in the preparation of capsules, gel, colloids and of different devices (e.g. contact lenses, gauzes, etc.). Macromolecules are also used in the preparation of controlled-release formulations of active ingredients. [0005]
  • Reviews of their characteristics and pharmaceutical uses are reported in [0006]
  • 1) C. Flansch et Al. Editors—“Comprehensive Medicinal Chemistry”—Pergamon Press, Oxford, 1990-Vol. 1-6; [0007]
  • 2) A. Wade and P. J. Wellers Editors—“Handbook of Pharmaceutical Excipients”—Ed. 1994—The Pharmaceutical Press. [0008]
  • Said macromolecules belong to different chemical families and may be either synthetic, or natural or semi-synthetic. [0009]
  • Examples of synthetic macromolecules include polyvinylpyrrolidone, polyoxyethylenealkyl ethers, polyvinyl alcohols, polymethacrylates. Examples of natural macromolecules include native hyaluronic acid (HY) and cellulose. [0010]
  • Examples of semi-synthetic macromolecules include carboxyalkylcelluloses, widely used in the food and personal care industries. These macromolecules are characterized by a linear or poorly branched structure. [0011]
  • A very important modification for increasing the chemical, enzymatic and mechanical strength is provided by cross-linking, which may be carried out both on synthetic and natural (more or less already modified) polymers. [0012]
  • Examples of cross-linked polymers include polymers used for the gastro-protection of tablets or capsules (polymethacrylates), as well as polymers used as emulsifiers, suspending agents, tablet hardeners (Carbopol), cross-linked hyaluronic acids, hereinafter discussed. [0013]
  • For the considered applications, and particularly for the preparation of invasive medical devices which have to be administered parenterally, said polymers must meet a number of requirements, of technical and regulatory kind. [0014]
  • The technical requirements include: [0015]
  • 1) high biocompatibility; [0016]
  • 2) resistance to enzymatic systems, both tissular or plasmatic (for injectable compositions) and gastrointestinal (for oral compositions). [0017]
  • In some cases a gradual degradation, for instance for the controlled release of a medicament, may be desirable. [0018]
  • This resistance is particularly important when the macromolecule is present in compositions/articles that must last for a long time, e.g. substitutes of the synovial liquid, films, sponges or gels as tissular antiadhesives in different kinds of surgery; in tissular engineering (artificial organs); artificial skins, in the treatment of burns and generally in aesthetic surgery; [0019]
  • 3) moldability into different shapes (gels, films, sponges, etc.); [0020]
  • 4) possibility to be sterilized chemically or physically without changing the product structure. [0021]
  • According to the regulatory requisites, the composition of the different production batches must be kept constant within very narrow limits; this implies that the production methods are standardized and that the base components have a very low intrinsic variability. [0022]
  • A possible cause of dishomogeneity for macromolecules derives from the dispersion of molecular weights. Said dishomogeneity becomes even higher as a consequence of cross-linking. This may be a serious drawback depending on the field of use and the applicative purposes of the final product. [0023]
  • EP-A-566118 (Kimberly-Clark) discloses cross-linked polysaccharides to be used as super-absorbents for diapers and similar articles. [0024]
  • The process described therein is based on the cross-linking of cellulose by formation of intermolecular amides, esters or ethers between polyamines, polyols or mixtures thereof and the carboxy group of polysaccharides. [0025]
  • The reaction is carried out by heating at about 80° C. the mixture of the polysaccharide with the polyol and/or polyamine. This process is certainly economic and suitable for large scale production where the reproducibility requirements are less stringent. [0026]
  • U.S. Pat. No. 5,465,055 discloses cross-linked polysaccharides (hyaluronic acid and alginic acid) obtained by esterification of COOH of the polysaccharide and OH groups of other molecules, without insertion of cross-linking arms. [0027]
  • WO 91/9119 discloses microcapsules for islets of Langerhans as biohybrid organs, consisting of alginic acid cross-linked with barium ions. [0028]
  • EP 190215 discloses the cross-linking of different polymers (carboxylated starches, dextran, celluloses) with di- or poly-functional epoxides. [0029]
  • The following cross-linking agents for hyaluronic acids have been proposed: [0030]
  • polyfunctional epoxides are disclosed in U.S. Pat. Nos. 4,716,224, 4,772,419, 4,716,154; [0031]
  • polyalcohols are disclosed in U.S. Pat. No. 4,957,744; [0032]
  • divinylsulfone is disclosed in U.S. Pat. Nos. [0033] 4,605,691, 4,636,524;
  • aldehydes are disclosed in U.S. Pat. Nos. 4,713,448 and 4,582,865; [0034]
  • carboxamides are disclosed in U.S. Pat. No. 5,356,833; [0035]
  • polycarboxylic acids are disclosed in EP-A-718312. [0036]
  • DISCLOSURE OF THE INVENTION
  • The invention refers to a process for the preparation of cross-linked polysaccharides containing carboxy groups, allowing complete control of cross-linking degree as well as high reproducibility in terms of constant characteristics of the final product. [0037]
  • The process of the invention comprises: [0038]
  • a) activation of the carboxy groups of the polysaccharide by reaction with suitable carboxy activating agents in anhydrous aprotic solvent; [0039]
  • b) reaction of the carboxy activated polysaccharide with a polyamine. [0040]
  • The obtained cross-linked polysaccharide, if desired, may be subjected to sulphation or hemisuccinylation of the free hydroxy groups. [0041]
  • The products obtainable by the process of the invention may also be complexed with metal ions such as zinc, copper or iron ions. [0042]
  • The carboxy-containing polysaccharide which may be used according to the invention may be of natural, synthetic or semi-synthetic origin. Examples of said polysaccharides include Hyaluronic acids (obtained from tissues or bacteria), carboxymethyldextran, carboxymethylcellulose, carboxymethyl-starch, alginic acids, cellulosic acid, N-carboxy-methyl or butyl glucans or chitosans; heparins with different molecular weights, optionally desulphated and succinylated, dermatan sulphates, Chondroitin sulphates, heparan sulphates, polyacrylic acids. [0043]
  • Hyaluronic acids, carboxymethylcellulose, heparins, alginic acids and polyacrylic acids are particularly preferred. [0044]
  • Said cross-linked polymers, obtained by different methods, are known and have been proposed for several uses (see, for instance, EP 566118, WO91/9119, U.S. Pat. No. 5,465,055, EP 190215, EP 718312, U.S. Pat. No. 4,716,224 discussed above). [0045]
  • The carboxy activating agents are usually those used in the peptide chemistry: examples of suitable agents include carbonyldiimidazole, carbonyltriazole, chloromethylpyridylium iodide (CMP-J), hydroxybenzotriazole, p-nitrophenol p-nitrophenyltrifluoroacetate, N-hydroxysuccinimide and the like. The use of chloromethylpyridylium iodide is particularly preferred. [0046]
  • The polyamines have preferably the following general formula: [0047]
  • R1—NH—A—NH—R2
  • wherein R[0048] 1 and R2, which are the same or different, are hydrogen, C1-C6 alkyl, phenyl or benzyl groups, A is a C2-C10 alkylene chain, preferably a C2-C6 alkylene chain, optionally substituted by hydroxy, carboxy, halogen, alkoxy, amino groups; a polyoxyalkylene chain of formula
  • [(CH2)n—O—(CH2)n]m
  • wherein n is 2 or 3 and m is an integer from 2 to 10; a C[0049] 5-C7 cycloalkyl group; an aryl or hetaryl group, preferably 1, 3 or 1,4-disubstituted benzene. A is preferably C2-C6 linear alkylene or a chain of formula
  • [(CH2)n—O—(CH2)n]m.
  • The cross-linking reaction is preferably carried out in a solvent selected from tetrahydrofuran, dimethylformamide or dimethyl sulfoxide, and the polysaccharide is preferably salified with a lipophilic cation, for example tetralkylammonium or other lipophilic organic bases. [0050]
  • The transformation of inorganic salts such as sodium salts, into suitable organic lipophilic salts may be carried out by known ion-exchange methods in homogeneous phase or by precipitation of the acidic component, followed by recovering of the latter and salification with the desired organic base. [0051]
  • The activation reaction of the carboxy groups is carried out in homogeneous phase and in anhydrous polar aprotic solvent. [0052]
  • The polyamine diluted in the same anhydrous solvent, is added to the solution of the activated ester, keeping the temperature from 0° C. to 30° C. The cross-linking reaction times range from 1 to 12 hours, also depending on the optional presence of suitable basic substances (e.g. triethylamine). [0053]
  • Generally, the final product is recovered by precipitation of the organic salt adding a different solvent to the reaction solvent or by evaporation of the latter, followed by centrifugation, washing with distilled water, repeated dispersions in the solutions of the desired alkali (for instance sodium, potassium), subsequent washing with water and final drying of the alkaline salt under vacuum or by lyophilization. [0054]
  • The cross-linking degree (C.L.D) may range within wide limits and may be adjusted by changing the amount of the carboxy activating agents, since the activation and the cross-linking reaction are substantially quantitative. [0055]
  • The cross-linked polysaccharides obtained according to the invention may be subjected to sulphation reaction of the hydroxy groups possibly present, usually by reaction with the pyridine-sulfur trioxide complex in dimethylformamide. [0056]
  • The reaction is carried out in heterogeneous phase at a temperature of 0-10° C. for times ranging from about 0.5 to about 6 hours. [0057]
  • The sulphation degree obtained is comprised within wide limits with respect to the total of the hydroxy groups and it may be adjusted by changing the temperature and reaction times. Generally, the sulphation degree (defined as equivalents of sulphate groups/g) may range from 1×10[0058] −6 to 6×10−6, preferably it is of 2×10−6 eq/g for a cross-linking degree of 0.5.
  • The cross-linked polymers obtained according to the invention, optionally sulphated, are able to complex metal ions such as zinc, copper or iron ions. [0059]
  • Said complexes may be obtained by dissolving or dispersing until complete swelling the product in water and adding under stirring, preferably at room temperature, a concentrated solution of an organic or inorganic metal salt, e.g. CuCl[0060] 2, ZnCl2, Fe2(SO4); after stirring for 12-24 hours, the complex is recovered by centrifugation or by precipitation following the addition of a different solvent (for example ethanol or acetone) or evaporation under vacuum; the recovered crude product is thoroughly washed with distilled water so as to remove the excess ions. The complexes are then lyophilized. The content of metal ions varies depending on the used operative conditions, particularly the polymer to ion molar ratios; concentration and pH of the solutions; reaction times and particularly cross-linking degree.
  • The process of the invention, by suitably adjusting the cross-linking and/or sulphation degree, allows the preparation of cross-linked carboxylated polysaccharides in a wide range of shapes, characterized by different properties such as viscoelasticity, hydration degree, complexing ability towards metal ions, ability to form hydrogels, moldability in films or sponges, mechanical strength of the final materials. [0061]
  • This allows their use in many medical fields, in the human and veterinary field, and in dermo-cosmetology. [0062]
  • The following examples further illustrate the invention.[0063]
  • EXAMPLE 1
  • Carboxymethylcellulose Gel 100% Cross-Linked with 1,3-diaminopropane. [0064]
  • 1.2×10[0065] −3 moles, with reference to the disaccharide unit of carboxymethyl cellulare TBA salt, were dissolved in 30 ml of DMF under N2 and with stirring. 0.32 g of chloromethylpyridylium iodide (1.2×10−3 moles) dissolved in 2 ml of DMF were added dropwise to the solution kept at a temperature of 0° C. with ice.
  • The molar ratio was 1 to 1 as carboxymethyl cellulose has one functional carboxylic group per disaccharide unit. After 20 minutes the solution was added with 2 ml of cross-linking 1,3-diaminopropane (0.006 moles), and immediately after also with 0.5 ml of triethylamine. A solid, jelly-like product formed which was washed with DMF, then placed in H[0066] 2O to completely swell.
  • Alternating washings with EtOH and H[0067] 2O were then carried out. After the last washing with EtOH, the product was freeze-dried.
  • I.R. (film; cm[0068] −1): 1650(—CO—NH—); no bending —COO at 1.400 about.
  • SD (Swelling Degree, in water and r.t., after 15′; gravimetric determination; calculated according to [0069] SD = W s - Wd Wd · 100 ,
    Figure US20040167098A1-20040826-M00001
  • where: [0070]
  • W[0071] s=weight of hydrated gel; Wd=weight of dry gel): 7.000
  • SEM (Scanning Electron Microscopy): the structure looks compact, with 15-35 μpers. [0072]
  • The product surface, by rabbit PRP (Platelet Rich Plasma) exposure, shows a very reduced presence of platelets or aggregates in comparison with equivalent product obtained by low density polypropylene (EC reference standard). [0073]
  • EXAMPLE 2
  • Carboxymethyl Cellulose Gel 50% Cross-Linked with 1,3-diaminopropane. [0074]
  • 1.2×10[0075] −3 moles, referred to the disaccharide unit of carboxymethyl cellulose, were dissolved in 30 ml of DMF under N2 and with stirring. 0.24 g of chloromethylpyridylium iodide (1.2×10−3 moles) dissolved in 2 ml of DMF were added dropwise to the solution kept at a temperature of 0° C. with ice. The molar ratio was 2/1.
  • After 20 minutes the solution was added with 2 ml of cross-linking 1,3-diaminopropane (3×10[0076] −3 moles), and immediately after also with 0.5 ml of triethylamine. A solid, jelly-like product formed which was washed with DMF, then placed in H2O to completely swell.
  • Alternating washings with EtOH and H[0077] 2O were then carried out. After the last washing with EtOH the product was freeze-dried.
  • I.R. (film; cm[0078] −1): 1650(—CO—NH—); no bending —COO at 1.400 about.
  • SD: 8.000 [0079]
  • SEM: presence of 13-25 μpers. [0080]
  • Platelet adhesion: as reported in Example 1. [0081]
  • EXAMPLE 3
  • Alginic acid gel 50% (100% with reference to disaccharide units) cross-linked with 1,3-diaminopropane. [0082]
  • The TBA salt of alginic has been prepared from the sodium salt by ionic exchange on strong cationic resin (Dovex) in H[0083] + form (i.e. acidic form), followed by neutralization with tetrabutylammonium hydroxide (TBA-OH) and final liophylisation.
  • 1.2×10[0084] −3 moles, refered to the monosaccharide unit, were dissolved in 30 ml of DMF under N2 and under stirring. 0.36 g of chloromethylpyridylium iodide (1.2×10−3 moles) dissolved in 2 ml of DMF were added dropwise to the solution kept at a temperature of 0° C. with ice. The molar ratio was 1/1.
  • After 20 minutes the solution was added with 6×10[0085] −3 moles of cross-linking 1,3-diaminopropane (0.024 moles), and immediately after also with 0.5 ml of triethylamine. A solid, jelly-like product formed which was washed with DMF, then placed in H2O to completely swell.
  • Alternating washings with EtOH and H[0086] 2O were then carried out. After the last washing with EtOH the product was freeze-dried.
  • IR (film; cm[0087] −1): 1635 (broad) (—CO—NH—): 1.400, about (—COO).
  • SD: 5.000 [0088]
  • SEM: the structure looks compact and without pores. [0089]
  • EXAMPLE 4
  • Preparation of hyaluronic acid cross-linked with C.L.D. =0.05 (5% of available carboxy groups). Cross-linking agent: 1,3-propanediamine. [0090]
  • Hyaluronic acid sodium salt (1×10[0091] −3 mol., with reference to the disaccharidic unit) were transformed in TBA salt, according to one of the following methods:
  • a) 1% aqueous solution of sodium hyaluronate is transformed in H[0092] + form by H+ cationic strong resin (Amberlite IR 120); the final solution is treated by a 0.5% solution of TBA-OH to about pH=9.
  • b) 1% aqueous solution of sodium hyaluronate is transformed in TBA salt solution by treating with a cationic weak resin in TBA[0093] + form. (Amberlite IRC 50)
  • In both cases, the final solutions are liophylised. The TBA salt is then dissolved in 15 ml of anhydrous DMF, under N[0094] 2, and—at 0° C.-0.02 g of cloromethypyridylium Iodide (CMPJ) in 2 ml of anhydrous DFM, are added dropwise to the stored solution of TBA salt.
  • The reaction mixture was then added with 0.1 ml of triethylamine and, then, dropwise, with a solution of 1,3-diaminopropane (d=0.88, in large excess, so as to make cross-linking of the activated carboxy groups easier) in 2 ml of anhydrous DMF. When the addition was over, the reaction mixture was stirred for at least 30′ and the solvent was then removed under reduced pressure, the residue was then taken up with DMF, which was subsequently removed by distillation; the residue was then treated with ethanol, ethanol-water and finally with water. [0095]
  • The product was then lyophilised and the residue subjected to analysis. [0096]
  • IR (film; cm[0097] −1): 1630 (—CO—NH); 1740 (—COOH, polysaccharide); 3200 (—NH—).
  • SD (Swelling Degree, in water and r.t., after 15′; gravimetric determination; calculated according to: [0098] SD W s - Wd Wd · 100 ,
    Figure US20040167098A1-20040826-M00002
  • where: [0099]
  • W[0100] s=weight of hydrated gel; Wd=weight of dry gel): 31.000
  • Cross-linking degree: 0.05 (5% of initially available carboxy groups). [0101]
  • EXAMPLE 5
  • Preparation of hyaluronic acid cross-linked with C.L.D. =0.05 (5% of the available carboxy groups). Cross-linking agent: 1,6-diaminohexane. [0102]
  • Activator: chloromethylpyridylium iodide. [0103]
  • According to the procedure and conditions reported in Example 4, using the same HY and the same activator, but 1,6-diaminohexane instead of 1,3-diaminopropane, the cross-linked derivative was obtained. [0104]
  • IR (film; cm[0105] −1): 1630 (—CO—NH); 1740 (—COOH polysaccharide); 3200 (—NH—).
  • EXAMPLE 6
  • Preparation of cross-linked hyaluronic acid, with C.L.D. =0.05 (5% of the available carboxy groups). Cross-linking agent: 0.0′-bis-(2-aminopropyl)PEG500. Activator: chloromethylpyridylium iodide [0106]
  • According to the procedure and conditions reported in Example 4 and using the same activator, but 0.0′-bis-(2-aminopropyl)PEG500 instead of 1,3-diaminopropane, the cross-linked derivative was obtained. [0107]
  • IR (film; cm[0108] −1): 1630 (—CO—NH); 1740 (—COOH polysaccharide); 3200 (—NH—)
  • SD: 31.000 [0109]
  • EXAMPLE 7
  • Preparation of cross-linked hyaluronic acids, with C.L.D.=0.3 (30% of the available carboxy groups). Cross-linking agent: 1,3-propanediamine. Activator: chloromethylpyridylium iodide. [0110]
  • 0.6 g of hyaluronic acid tributylammonium salt (1×10[0111] −3 mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of DMF under nitrogen. 0.08 g of chloromethylpyridylium iodide (3.5×10−4 mol) dissolved in 2 ml of DMF were added dropwise to the stirred solution kept at 0° C. The molar ratio was therefore about 3/1.
  • After 20 minutes 2 ml of 1,3-diaminopropane (0.024 mol) were added, followed immediately by 0.5 ml of triethylamine. A solid, gelatinous product was obtained, the product was then swelled with water and washed again with ethanol. [0112]
  • The final product, after lyophilisation, shows at the scanning microscope an irregular pattern with smooth zones alternating to spongy zones. [0113]
  • The cross-linking degree was 0.3 (30% of initially available carboxy groups) [0114]
  • IR (film; cm[0115] −1): 1740 (—COOH); 1630 (—CO—NH); 1610 (—COO—); 1560 (—CO—NH—)
  • EXAMPLE 8
  • Preparation of hyaluronic acid cross-linked with C.L.D.=0.5 (50% of the available carboxy groups). Cross-linking agent: 1,3-propanediamine. Activator: chloromethylpyridylium iodide. [0116]
  • 0.6 g of hyaluronic acid tributylammonium salt (HY TBA) (1×10[0117] −3 mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of DMF under nitrogen. 0.15 g of chloromethylpyridylium iodide (CMPJ) (6×10−6 mol) dissolved in 2 ml of DMF were added dropwise to the solution, kept at 0° C. The molar ratio was 2HY.TBA:1 CMPJ. After 20 minutes, 2 ml of 1,3 diaminopropane (0.024 mol.) were added to the solution.
  • 0.5 ml of triethylamine were added thereafter. [0118]
  • A solid, gelly-like product was obtained and thoroughly washed with DMF. [0119]
  • After evaporating DMF, the product was swelled in water and washed with ethanol before lyophilization. [0120]
  • The obtained product had a cross-linking degree of 0.5 and showed at the scanning microscope a grainy aspect interspaced by large meshes. At higher magnitudes, the two morphologies appear identical and show round-shaped protrusions a few microns in diameter. [0121]
  • IR (film; cm[0122] −1): 1740 (—COOH); 1630 (—CO—NH—); 1610 (—COO); 1560 (—CO—NH—);
  • The gels were subjected to swelling in PBS and the max swelling ability was evaluated. [0123]
  • SD=23.500 [0124]
  • NMR=(13 C; ppm): 29.3 and 39.8 (—CH[0125] 2—CH2—CH2— propanediamine link); 172.5
    Figure US20040167098A1-20040826-C00001
  • The rheological properties evaluated on Bohlin VOR Rheometer, at the temperature of 23±0.1° C., show that the dynamic elastic module G′ (100 Pa at 10 Hz) identical at the two considered concentrations (10 and 20 mg/ml) is always higher than the viscous dynamic module (G″ 40 Pa for 20 mg at 10 Hz and 20 Pa for 10 mg at 10 Hz). [0126]
  • EXAMPLES 9-12
  • According to the methods disclosed in the previous examples, the cross-linked hyaluronic acid derivatives having the characteristics summarised in the following table 1, were obtained, starting from 1×10[0127] −3 mol (0.6 g) of hyaluronic acid tributylammonium salt.
  • The obtained derivatives had the following properties: [0128]
    TABLE 1
    Scanning
    Cross- Amount Cross- Electron
    linking agent (g) of linking Microscopy
    Ex (mol) CMPJ (mol) degree SD NMR (13) (ppm) I.R. (film) (cm−1) (SEM)
     9 1,3-propane- diamine (0.024) 0.6 g (1.210−3) (100%) 13.200
    Figure US20040167098A1-20040826-C00002
    Figure US20040167098A1-20040826-C00003
    Homogeneouns, ondulated morphology.
    10 0,0′-1-bis-(-2-di- 0.15 g (50%) 9.000 Alternating
    aminopropyl) (6 × 10−4) smooth areas
    PEG 500 (0.022) and meshes,
    circular
    protrusions a
    few microns in
    size.
    11 0,0′-bis (2-amino- 0.15 g (50%) 6.100 Two
    propyl) - (6 × 10−4) morphologically
    PEG 800 (0.022) different zones,
    a first one
    ondulated and a
    second with
    hole-like
    structures.
    12 1,6-diamino- hexane (0.023) 0.15 g (6 × 10−4) (50%) 8.000 169.46(—CO—NH— of cross- linking); 74.04/76.80/83.17/80.41(—CH2—of cross-linking arm)
    Figure US20040167098A1-20040826-C00004
    Smooth surface with protrusions having a few microns in size.
  • EXAMPLE 13
  • Sulphation of 50% cross-linked HY, [0129]
  • The derivative obtained in example 8 was dispersed in 5 ml DMF under strong stirring and nitrogen atmosphere. [0130]
  • A solution of 1 g of SO[0131] 3/pyridine in mol of DMF was added at 0° C. and stirred for 3 hours. The reaction was blocked by adding an excess of H2O (50 ml) and the pH adjusted to 9 with 0.1M NaOH.
  • The product was thoroughly washed with ethanol and H[0132] 2O and then lyophilized.
  • The IR spectrum shows, in addition to the bands of the starting product, a peak at 1260 cm[0133] −1 and a stronger band at 1025 cm−1.
  • The gel swells in PBS with SD=33.000. Higher resolution 13C NMR spectrum shows the signals in H[0134] 2O at 37° C. reported in table 2. The intensity of the NMR signals at 29.3 and 38.8 ppm (—CH2—) and the signal at 172.5 ppm (CONH) confirm a cross-linking degree of about 50%.
  • The rheological properties are characterised by dynamic elastic modules G′ (2500 Pa with 20 mg and 1000 Pa with 10 mg at 10 Hz) which are always higher than the dynamic viscous modules G″ (600 Pa with 20 mg and 150 Pa with 10 mg at 10 Hz) and much higher than the corresponding values obtained with non-sulphated HY (13 at 50%—example 5). This compound has a thrombin time (TT) higher (61±5”) than the control (14.0″) and the corresponding not cross-linked (14.6″). [0135]
  • The compound was also active in the PRP test using stressed rabbit. [0136]
    TABLE 2
    Table: 13C Chemical shift
    C-1 C-2 C-3 C-4 C-5 x-C═O y-CH3
    103.5 57.3 85.4  71.3 78.7 178.0 25.3 ppm
    C-1′ C-2′ C-3′ C-4′ C-5′ 6-C═O
    105.9 75.2 76.4  82.8 78.6 176.2 ppm
    1-CH2 2-CH2 3-CH2 6′-C═O CROSS-LINKING
     39.8 29.3 39.8 172.5 ppm
  • EXAMPLE 14
  • Sulphation of Alginic Acid GEL [0137]
  • The cross-linked product after treatment with EtOH was freeze-dried to remove completely humidity and subjected to sulphation of the alcohol groups. [0138]
  • 100 mg of cross-linked product dispersed in 5 ml of DMF were added with a SO[0139] 3-pyridine solution of (800 mg in 2 ml of DMF). The reaction should be carried out at 0° C., under nitrogen and with constant stirring for 2 hours.
  • It is mandatory for the product not to adsorb humidity, as it inhibits the reaction. [0140]
  • After 2 hours H[0141] 2O was added pH was adjusted to 9 by a 1M solution of NaOH, thereby freeing pyridine.
  • The thus sulphated product was purified in EtOH. [0142]
  • The analysis of purified products, shows: [0143]
  • IR (film; cm[0144] −1) 1263 (stretching SO)
  • Equivalents of SO[0145] 3 groups/g gel (by toluidine complexes):
  • 5% cross linked gel: 6×10[0146] −5
  • 50% cross linked gel: 2×10[0147] −5
  • 100% cross linked gel: 3×10[0148] −5
  • SD [0149]
  • 5% cross linked gel: 19×10[0150] 3
  • 50% cross linked gel: 9×10[0151] −3
  • 100% cross linked gel: 7×10[0152] −3
  • EXAMPLE 15
  • Using the same methodology, the sulphated derivatives of 50% cross-linked products according to example 10, 11 and 12, have been synthetized. [0153]
  • Colorimetric characteristics of the sulphated derivatives are reported in table 3 together with that of the products deriving from examples 8 and 13. [0154]
    TABLE 3
    CROSSLINKED POLYMER
    (50% CROSS-LINKING ΔHa Tg
    DEGREE) [J/g] [° C.] ΔHb [J/g] Wt % water
    C.L.Hyal-1,3 (Ex. 8) 276 51 42 12
    C.L.HyalS-1,3 (Ex. 13) 357 64 53 16
    C.L.Hyal-1,6 (Ex. 12) 327 64 58 16
    C.L.HyalS-1,6 465 64 65 20
    5 C.L.Hyal-P500.2NH2 (Ex. 10) 239 45 72 10
    6 C.L.HyalS-P500.2NH2 384 69 113 16
    7 C.L.Hyal-P800.2NH2 (Ex. 11) 179 73 30 10
    8 C.L.HyalS-P800.2NH2 206 76 52 10
    Hyal ITBA 164 130 5
  • EXAMPLE 16
  • Suphation of Carboxymethylcellulose Gel. [0155]
  • Following the procedure and conditions reported in Example 14, the sulphated derivative was obtained. [0156]
  • Equivalents of SO[0157] 3 Groups/g:
  • a—CMC 5% cross linked: 8×10[0158] −6
  • b—CMC 50% cross linked: 7×10[0159] −6
  • c—CMC 100% cross linked: 4×10[0160] −6
  • SD [0161]
  • a: 20×10[0162] −3
  • b: 12×10[0163] −3
  • c: 9×10[0164] −3

Claims (7)

1. A product having application in the medical, pharmaceutical and dermo-cosmetic fields comprising a cross-linked polysaccharide in which cross-linkage exists only through amide bonds between carboxy groups of the polysaccharide and amino groupss of a polyamine.
2. A product according to claim 1 in which it is complexed with zinc, copper or iron ions.
3. A product according to claim 1 in which the it sulfated with a pyridine-sulfur trioxide complex.
4. A pharmaceutical composition in which the principal ingredient is a product according to claim 1.
5. A product having application in the medical, pharmaceutical and dermo-cosmetic fields comprising a cross-linked polysaccharide in which cross-linking occurs only through amide bonds between carboxy groups of the polysaccharide and amino groups of a polyamine in which the polysaccharide is selected from the group consisting of hyaluronic acids, carboxymethyldextran, carboxymethylcellulose, carboxymethylstarch, alginic acids, cellulose acid, N-carboxymethyl or butyl glucans or chitosans, heparins with different molecular weights, optionally desulfated and succinylated, dermatan sulfates, chodroitin sulfates and heparin sulfates obtained by (a) reacting the carboxy groups of a polysaccharide in an aqueous aprotic solvent using a suitable carboxy activating agent, (b) reacting the carboxy activated polysaccharide with a polyamine selected from the group having the formula R1—NH-A-NH—R2 herein R1 and R2, which may be the same or different, are hydrogen, C1-C6 alkyl, phenyl, or benzyl groups; A is a C2-C10 alkylene chain; a polyoxylene chain of the formula [(CH2)n]m wherein n is 2 or 3 and m is an interger from 2 to 10, a C5-C7 cycloalkyl group or an aryl or heterocyclic group and (c) recovering the resultant cross-linked polsaccharide.
6. A product according to claim 4 in which it is complexed with zinc, copper or iron ions.
7. A product according to claim 4 in which it is sulfated with a pyridine-sulfur trioxide complex.
US10/787,736 1998-11-11 2004-02-26 Cross-linked polysaccharides Abandoned US20040167098A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/787,736 US20040167098A1 (en) 1998-11-11 2004-02-26 Cross-linked polysaccharides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI98A002443 1998-11-11
IT1998MI002443A IT1303738B1 (en) 1998-11-11 1998-11-11 CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS.
US09/830,744 US6734298B1 (en) 1998-11-11 1999-11-09 Cross-linking process of carboxylated polysaccharides
US10/787,736 US20040167098A1 (en) 1998-11-11 2004-02-26 Cross-linked polysaccharides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/830,744 Division US6734298B1 (en) 1998-11-11 1999-11-09 Cross-linking process of carboxylated polysaccharides

Publications (1)

Publication Number Publication Date
US20040167098A1 true US20040167098A1 (en) 2004-08-26

Family

ID=11381036

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/830,744 Expired - Lifetime US6734298B1 (en) 1998-11-11 1999-11-09 Cross-linking process of carboxylated polysaccharides
US10/787,736 Abandoned US20040167098A1 (en) 1998-11-11 2004-02-26 Cross-linked polysaccharides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/830,744 Expired - Lifetime US6734298B1 (en) 1998-11-11 1999-11-09 Cross-linking process of carboxylated polysaccharides

Country Status (25)

Country Link
US (2) US6734298B1 (en)
EP (1) EP1137670B1 (en)
JP (1) JP2002529549A (en)
KR (1) KR100685454B1 (en)
CN (1) CN1144818C (en)
AT (1) ATE291590T1 (en)
AU (1) AU756158B2 (en)
BR (1) BR9915238A (en)
CA (1) CA2350665A1 (en)
CZ (1) CZ303485B6 (en)
DE (1) DE69924407T2 (en)
DK (1) DK1137670T3 (en)
ES (1) ES2237971T3 (en)
HK (1) HK1041010B (en)
HU (1) HU227731B1 (en)
IL (1) IL143064A0 (en)
IT (1) IT1303738B1 (en)
NO (1) NO20012316L (en)
NZ (1) NZ511308A (en)
PT (1) PT1137670E (en)
RU (1) RU2230073C2 (en)
SI (1) SI1137670T1 (en)
TR (1) TR200101325T2 (en)
WO (1) WO2000027886A1 (en)
ZA (1) ZA200103800B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012017288A3 (en) * 2010-08-04 2012-03-29 Carlo Ghisalberti Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
KR20170122179A (en) 2015-02-27 2017-11-03 각코호우징 조쇼 가쿠엔 Polysaccharide derivatives having membrane permeable peptide chains

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD980037A1 (en) * 1998-02-25 1999-08-25 Fidia Advanced Biopolymers Srl SULFATED HYALURONIC ACID AND ITS DERIVATIVES COVALENTLY LINKED TO SYNTHETIC POLYMERS FOR THE PREPARATION OF BIOMATERIALS AND FOR COATING
IT1303738B1 (en) 1998-11-11 2001-02-23 Aquisitio S P A CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS.
IT1303735B1 (en) * 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S CROSS-LINKED HYALURONIC ACIDS AND THEIR MEDICAL USES.
FR2799196B1 (en) * 1999-10-04 2002-02-08 Sod Conseils Rech Applic CROSSLINKED COPOLYMERS BASED ON NON-CROSSLINKED POLYCARBOXYLIC COPOLYMERS
KR100375299B1 (en) * 2000-10-10 2003-03-10 주식회사 엘지생명과학 Crosslinked derivatives of hyaluronic acid by amide formation and their preparation methods
US6500947B1 (en) 2001-08-24 2002-12-31 Weyerhaeuser Company Superabsorbent polymer
KR100493461B1 (en) * 2002-02-27 2005-06-07 재단법인서울대학교산학협력재단 Natural polymers bonded adhesion molecular, their preparation and their use
FR2839312A1 (en) * 2002-05-03 2003-11-07 Roquette Freres Production of an amidated amylaceous material, e.g. useful in papermaking, comprises reacting a dry or semidry carboxy-functional amylaceous material with an amine at elevated temperature in the absence of solvent
KR20040009891A (en) * 2002-07-26 2004-01-31 주식회사 엘지생명과학 Hyaluronic Acid Derivative Gel and Method for Preparing the Same
KR100523953B1 (en) * 2002-08-27 2005-10-25 주식회사 엘지생명과학 Microbeads of natural polysaccharide and hyaluronic acid and processes for preparing the same
DE10256558A1 (en) * 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Esters of polysaccharide aldonic acids, process for their preparation and use for coupling to active pharmaceutical ingredients
EP1595892A4 (en) 2003-02-21 2007-06-20 Terumo Corp Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition and medical treatment material
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
JP4669919B2 (en) * 2003-06-06 2011-04-13 コスモテック株式会社 Medical composition
US8519058B2 (en) 2004-02-23 2013-08-27 E I Du Pont De Nemours And Company Crosslinked polymers containing biomass derived materials
JP4566189B2 (en) * 2004-03-15 2010-10-20 テルモ株式会社 Anti-adhesive material
KR100863870B1 (en) 2004-06-21 2008-10-15 에보닉 스톡하우젠 게엠베하 Water absorbing polysaccharide and method for producing the same
ITMI20041373A1 (en) 2004-07-09 2004-10-09 Lima Lto S P A N-METHYL-CARBOXYMETHYLCELLULOSE ACID ALGINIC OR CARBOXYMETALAMIDE
US7541396B2 (en) 2004-12-29 2009-06-02 Weyerhaeuser Nr Company Method for making carboxyalkyl cellulose
US7241836B2 (en) * 2004-12-29 2007-07-10 Weyerhaeuser Co. Method of crosslinking a mixture of carboxylated polymers using a triazine crosslinking activator
US7393905B2 (en) * 2004-12-29 2008-07-01 Weyerhaeuser Company Crosslinked mixed carboxylated polymer network
US7300965B2 (en) 2004-12-29 2007-11-27 Weyerhaeuser Company Mixed polymer network
US7230049B2 (en) * 2004-12-29 2007-06-12 Weyerhaeuser Co. Method of crosslinking a carboxylated polymer using a triazine crosslinking activator
US20060142476A1 (en) * 2004-12-29 2006-06-29 Weerawarna S A Crosslinked carboxylated polymer
AU2006286158A1 (en) * 2005-09-02 2007-03-08 Colbar Lifescience Ltd. Cross-linked polysaccharide and protein matrices and methods for their preparation
RU2486907C2 (en) * 2006-12-04 2013-07-10 Джонс Хопкинс Юниверсити Imidised biopolymer adhesive and hydrogel
KR100825519B1 (en) 2007-01-05 2008-04-25 주식회사 바이오폴리메드 A chitosan based polymer conjugate and a method for producing the same
US20080293637A1 (en) * 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
JP5670196B2 (en) 2007-11-16 2015-02-18 バイセプト セラピューティクス、インク. Compositions and methods for treating purpura
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
ES2829971T3 (en) 2008-09-02 2021-06-02 Tautona Group Lp Hyaluronic acid threads and / or derivatives thereof, methods to manufacture them and uses thereof
US8361926B2 (en) * 2008-11-25 2013-01-29 Evonik Stockhausen, Llc Water-absorbing polysaccharide and method for producing the same
EP2413894B1 (en) * 2009-04-02 2017-01-04 Allergan, Inc. Hair-like shaped hydrogels for soft tissue augmentation
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
KR101764451B1 (en) 2010-03-12 2017-08-02 알러간 인더스트리 에스에이에스 A Fluid Composition Comprising A Hyaluronan Polymer and Mannitol For Improving Skin Condition
PL3078388T3 (en) 2010-03-22 2019-08-30 Allergan, Inc. Cross-linked hydrogels for soft tissue augmentation
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
KR102312056B1 (en) 2011-06-03 2021-10-12 알러간 인더스트리 에스에이에스 Dermal filler compositions including antioxidants
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
CN103113495A (en) * 2013-02-03 2013-05-22 江苏天竹化工科技有限公司 Photopolymerizable hyaluronic acid derivative and preparation method thereof
ITUD20130119A1 (en) * 2013-09-12 2015-03-13 Limacorporate Spa BIOCOMPATIBLE IDROGEL FOR BIOMEDICAL OR PHARMACEUTICAL USE, INTERMEDIATE POLYMER TO REALIZE THE BIOCOMPATIBLE IDROGEL AND ITS APPLICATION METHOD
ES2811269T3 (en) 2014-01-31 2021-03-11 Seikagaku Kogyo Co Ltd Diamine crosslinking agent, acid polysaccharide crosslinking body and medical material
ES2761558T3 (en) 2014-09-30 2020-05-20 Allergan Ind Sas Stable hydrogel compositions including additives
ES2938482T3 (en) 2015-01-16 2023-04-11 Seikagaku Kogyo Co Ltd Cross-linked chondroitin sulfate, composition containing the same and treatment agent for eye disease
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
WO2016159159A1 (en) * 2015-03-31 2016-10-06 キユーピー株式会社 Hyaluronic acid derivative and manufacturing method therefor and cosmetics, food composition, and pharmaceutical composition containing hyaluronic acid derivative
CZ306479B6 (en) * 2015-06-15 2017-02-08 Contipro A.S. A method of crosslinking polysaccharides by using photolabile protecting groups
GB201511218D0 (en) 2015-06-25 2015-08-12 Goe Ip As Reservoir treatments
CN105566511B (en) * 2016-01-27 2017-11-03 天津医科大学 Electric charge overturns pulullan polysaccharide derivative and its preparation method and use
CN110961057A (en) * 2020-01-16 2020-04-07 江苏罗格斯生物科技有限公司 Green biological hydrogel conveying system and preparation method thereof
RU2743941C1 (en) * 2020-07-29 2021-03-01 Федеральное государственное бюджетное учреждение науки Институт химии Дальневосточного отделения Российской академии наук (ИХ ДВО РАН) Method for producing biopolymeric hydrogel
CN114230678B (en) * 2021-12-13 2023-09-01 珠海通桥医疗科技有限公司 Photocrosslinked hydrogel embolism system for intravascular treatment and application method
CN114507359A (en) * 2022-02-17 2022-05-17 浙江大学 Preparation method of modified material of lignosulfonate and application of modified material in nano pesticide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5944753A (en) * 1991-08-16 1999-08-31 Galin; Miles A. Medicament coated refractive anterior chamber ocular implant
US6831172B1 (en) * 1998-11-11 2004-12-14 Farmila-Thea Farmaceutici S.P.A. Cross-linked hyaluronic acids and medical uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5257102A (en) * 1975-11-06 1977-05-11 Sumitomo Chemical Co Process for preparing carboxylic acid amide
US4716224A (en) * 1984-05-04 1987-12-29 Seikagaku Kogyo Co. Ltd. Crosslinked hyaluronic acid and its use
SE442820B (en) * 1984-06-08 1986-02-03 Pharmacia Ab GEL OF THE CROSS-BOND HYALURONIC ACID FOR USE AS A GLASS BODY SUBSTITUTE
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4605691A (en) * 1984-12-06 1986-08-12 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (en) * 1985-03-01 1986-09-02 Pharmacia Ab FORMAT CREATES AND PROCEDURES FOR ITS PREPARATION
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
IT1184161B (en) * 1985-03-14 1987-10-22 Franco Conti CHITOSAN DERIVATIVES CONSTITUTED BY COORDINATION COMPLEXES WITH FERROUS IONS
IT1198449B (en) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID
IT1219587B (en) * 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
CZ714489A3 (en) * 1989-12-18 1993-03-17 Kery Vladimir method of binding biologically active substances containing an amine group to polysaccharides
WO1991016881A1 (en) * 1990-05-04 1991-11-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Colonic drug delivery system
JP2855307B2 (en) * 1992-02-05 1999-02-10 生化学工業株式会社 Photoreactive glycosaminoglycans, cross-linked glycosaminoglycans and methods for producing them
CA2076732C (en) * 1992-04-17 2006-05-09 Kimberly-Clark Worldwide, Inc. Modified polysaccharides having improved absorbent properties and process for the preparation thereof
US5550189A (en) * 1992-04-17 1996-08-27 Kimberly-Clark Corporation Modified polysaccharides having improved absorbent properties and process for the preparation thereof
JP3107726B2 (en) * 1994-05-13 2000-11-13 株式会社クラレ Water-swellable polymer gel
US5690961A (en) * 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
JP4018181B2 (en) * 1995-11-07 2007-12-05 生化学工業株式会社 Glycosaminoglycan derivative and process for producing the same
JPH09176204A (en) * 1995-12-28 1997-07-08 Kazukiyo Kobayashi Functional material containing sialoglycochain and its synthesis
JPH09278803A (en) * 1996-04-09 1997-10-28 Kuraray Co Ltd Medical treatment material
JP3413062B2 (en) * 1996-06-19 2003-06-03 キヤノン株式会社 Polymer compound containing sugar chain polymer compound and decomposition method thereof
FR2752843B1 (en) * 1996-08-30 1998-10-16 Sod Conseils Rech Applic CROSSLINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS SUPPORTS OF PHARMACEUTICAL COMPOSITIONS
EP0927196B1 (en) * 1996-09-19 2008-11-05 The Regents Of The University Of Michigan Polymers containing polysaccharides such as alginates or modified alginates
US6630457B1 (en) * 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
IT1303738B1 (en) 1998-11-11 2001-02-23 Aquisitio S P A CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5944753A (en) * 1991-08-16 1999-08-31 Galin; Miles A. Medicament coated refractive anterior chamber ocular implant
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5874417A (en) * 1993-11-30 1999-02-23 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US6831172B1 (en) * 1998-11-11 2004-12-14 Farmila-Thea Farmaceutici S.P.A. Cross-linked hyaluronic acids and medical uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012017288A3 (en) * 2010-08-04 2012-03-29 Carlo Ghisalberti Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
KR20170122179A (en) 2015-02-27 2017-11-03 각코호우징 조쇼 가쿠엔 Polysaccharide derivatives having membrane permeable peptide chains
US10793603B2 (en) 2015-02-27 2020-10-06 Josho Gakuen Educational Foundation Polysaccharide derivative having membrane-permeable peptide chain

Also Published As

Publication number Publication date
HK1041010B (en) 2004-10-08
HUP0104075A2 (en) 2002-04-29
PT1137670E (en) 2005-06-30
ZA200103800B (en) 2002-06-10
ES2237971T3 (en) 2005-08-01
HK1041010A1 (en) 2002-06-28
KR20010101002A (en) 2001-11-14
RU2230073C2 (en) 2004-06-10
AU1380300A (en) 2000-05-29
BR9915238A (en) 2001-07-24
DK1137670T3 (en) 2005-07-25
DE69924407T2 (en) 2005-08-11
ATE291590T1 (en) 2005-04-15
NO20012316L (en) 2001-07-06
CN1325409A (en) 2001-12-05
EP1137670B1 (en) 2005-03-23
US6734298B1 (en) 2004-05-11
DE69924407D1 (en) 2005-04-28
IT1303738B1 (en) 2001-02-23
ITMI982443A1 (en) 2000-05-11
NZ511308A (en) 2003-06-30
CA2350665A1 (en) 2000-05-18
HU227731B1 (en) 2012-01-30
WO2000027886A1 (en) 2000-05-18
JP2002529549A (en) 2002-09-10
SI1137670T1 (en) 2005-06-30
HUP0104075A3 (en) 2003-03-28
IL143064A0 (en) 2002-04-21
KR100685454B1 (en) 2007-02-23
AU756158B2 (en) 2003-01-02
EP1137670A1 (en) 2001-10-04
TR200101325T2 (en) 2001-10-22
NO20012316D0 (en) 2001-05-10
CZ20011651A3 (en) 2001-12-12
CN1144818C (en) 2004-04-07
CZ303485B6 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
US6734298B1 (en) Cross-linking process of carboxylated polysaccharides
KR100674177B1 (en) Cross-linked hyaluronic acids and medical uses thereof
Gómez-Mascaraque et al. Oxidized dextrins as alternative crosslinking agents for polysaccharides: application to hydrogels of agarose–chitosan
US7651702B2 (en) Crosslinking hyaluronan and chitosanic polymers
EP1163274B1 (en) Process for cross-linking hyaluronic acid to polymers
US8575129B2 (en) Amides of hyaluronic acid and the derivatives thereof and a process for their preparation
US7683038B2 (en) Percarboxylated polysaccharides, and a process for their preparation
Bam et al. Design of biostable scaffold based on collagen crosslinked by dialdehyde chitosan with presence of gallic acid
AU2001252180B2 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
US20110117198A1 (en) Compositions of semi-interpenetrating polymer network
WO2013164782A1 (en) Shape-memory cross-linked polysaccharides
de Azevedo Aldehyde-functionalized chitosan and cellulose: chitosan composites: application as drug carriers and vascular bypass grafts
MXPA01004723A (en) Cross-linking process of carboxylated polysaccharides
RU2659175C1 (en) Composition on the basis of bacterial cellulose and hyaluronic acid
EP4341303A1 (en) Mixtures of polysaccharides and polyaminosaccharides with improved rheological properties
López-Saucedo et al. Hydrogels Based on Natural and/or Synthetic Polymers

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SIGMA ITALIA SPA, ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FARMILA-THEA FARMACEUTICI S.P.A.;REEL/FRAME:019140/0399

Effective date: 20060921